Related Experiment Video

Updated: Aug 18, 2026

A Rat Model of Compound Acne
03:10

A Rat Model of Compound Acne

Published on: November 1, 2024

A practical approach for the use of oral isotretinoin for infantile acne

Cheryl J Barnes1, Lawrence F Eichenfield, Jungho Lee

  • 1Division of Pediatric and Adolescent Dermatology, Department of Pediatrics, University of California San Diego, San Diego, California 92123, USA.

Pediatric Dermatology
|April 5, 2005
PubMed

Insights

Infantile cystic acne, a rare condition in infants, can be effectively treated with oral isotretinoin. This study details successful treatment protocols and emphasizes careful monitoring for potential side effects.

Area of Science:

  • Pediatric Dermatology
  • Dermatology
  • Neonatology

Background:

  • Infantile acne is a rare skin condition affecting infants aged 1-16 months, predominantly in males.
  • Lesions can manifest as comedones, papulopustules, or cysts, posing a therapeutic challenge.
  • Existing treatments include topical agents and antibiotics, but severe cases may require alternative approaches.

Observation:

  • This study reports on two infants diagnosed with recalcitrant infantile cystic acne.
  • Both patients were successfully treated with oral isotretinoin, a medication typically reserved for severe cases.
  • Treatment dosages ranged from 0.2 to 1.5 mg/kg/day over 5 to 14 months.

Findings:

  • Oral isotretinoin demonstrated significant efficacy in resolving severe infantile cystic acne in the presented cases.
  • The therapeutic response was observed across a spectrum of dosages and treatment durations.
  • No adverse events were detailed, but monthly monitoring is advised due to known isotretinoin side effects.

Implications:

  • Oral isotretinoin offers a viable treatment option for severe infantile cystic acne unresponsive to conventional therapies.
  • Further research into optimal dosing and long-term outcomes of isotretinoin in infants is warranted.
  • Clinical guidelines may benefit from incorporating oral isotretinoin for recalcitrant infantile acne cases, with strict patient monitoring.

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...